

STANDARD DECLARATION OF INTERESTS (DOI) FORM

Definitions:

“**Activity**” or “**Activities**” (capitalised ‘A’) means an activity or activities of or under the Group of Chief Scientific Advisors for instance in its formation as Coordination Group or in sub-groups, or that or those in relation thereto, for example, SAPEA Working Groups.

"**Conflict of interest**" means any situation where an individual has an interest that may compromise or be reasonably perceived to compromise the individual’s capacity to act independently and in the public interest when providing advice to the Commission in relation to Activities performed.

"**Immediate family member**" means the individual’s spouse, children and parents. "Spouse" includes a partner with whom the individual has a registered non marital regime. "Children" means the child(ren) the individual and the spouse have in common, the own child(ren) of the individual and the own child(ren) of the spouse.

"**Legal entity**" means any commercial business, industry association, consultancy, research institution or other enterprise whose funding is significantly derived from commercial sources. It also includes independent own commercial businesses, law offices, consultancies or similar.

"**Body**" means a governmental, international or non-profit organisation.

"**Meeting**" includes a series or cycle of meetings.

Please answer each of the questions below. If the answer to any of the questions is "yes", please briefly describe relevant interests and circumstances, as appropriate.

If you do not describe relevant interests and your DoI form is considered to be incomplete, or if declared interests are considered to constitute a Conflict of Interest, you may be excluded from all or part of the Activities.

First name: **Harry (Henricus) J.**

Family name: **de Koning**

Date: **03.02.2022**

Description of the Activity: **Co-chair of SAPEA cancer screening project**

1 EMPLOYMENT CONSULTANCY AND LEGAL REPRESENTATION

	Within the past 5 years, were you employed or have you had any other professional relationship with a natural or legal entity, or held any non-remunerated post in a legal entity or other body with an interest in the field of the Activity in question?	yes	
--	---	-----	--

<i>Ia</i>	<i>Employment</i>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
<i>Ib</i>	<i>Consultancy, including services as an advisor</i>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
<i>Ic</i>	<i>Non-remunerated post</i>	<input type="checkbox"/>	<input type="checkbox"/>
<i>Id</i>	<i>Legal representation</i>	<input type="checkbox"/>	<input type="checkbox"/>

<i>activity</i>	<i>time period (from... until month/year)</i>	<i>name of entity or body</i>	<i>description</i>
Coordinator of EU-TOPIA project (Horizon 2020 funded project)	September 2015- August 2020	EU-TOPIA: Towards improved screening for breast, cervical and colorectal cancer in all of Europe	The objective of EU-TOPIA was to systematically evaluate and quantify the harms and benefits of the running programmes for breast, cervical, and colorectal cancer in all European countries, and identify ways to improve health outcomes and equity for citizens.
Coordinator of EU-TOPIA-EAST (Horizon 2020 funded project)	May 2021-April 2026	EU-TOPIA-EAST: A follow up project from EU-TOPIA	Builds upon the expertise and tools developed in the previous EU-TOPIA project. Focus is on action plans for cancer screening in Georgia, Romania and Montenegro.
Investigator in MyPEBS project (Horizon 2020 funded project). Responsible for economic modelling.	2018-2025	MyPeBS (My Personal Breast Screening)	The project is a major European initiative. This unique international clinical study compares a personalised risk-based screening strategy (based on the individual women's risk of developing breast cancer) to standard screening among 85,000 women aged 40 to 70 in 6

			countries: Belgium, France, Israel, Italy, United Kingdom and Spain.
Coordinator of 4-IN-THE-LUNG-RUN project (Horizon 2020 funded project)	January 2020-December 2024	4-IN-THE -LUNG-RUN: towards INDividually tailored INVitations, screening INTervals, and INtegrated co-morbidity reducing strategies in lung cancer screening	The EU-funded 4-IN THE LUNG RUN project consists of a randomised controlled trial engaging 24 000 individuals aiming to evaluate when it is safe to increase risk-based screening intervals after a negative baseline CT. It is a multi-center implementation trial in 5 countries, with an additional focus on individual optimal recruitment and smoking cessation strategies, co-morbidity reducing strategies (like the use of a calcium score for CVD), and biomarkers
Principal Investigator in CANCON project	2014-2018	CANCON (European Guide on Quality Improvement in Comprehensive Cancer Control)	CANCON is co-funded by the Health Programme of the European Union. The Guide aims to help to reduce not only the cancer burden throughout the EU but also the inequalities in cancer control and care that exist between Member states. The Guide is meant for governments, parliamentarians, health care providers and funders, and cancer care professionals at every level
Professor of Public Health and Screening Evaluation	2008-present	Erasmus MC University Medical Centre Rotterdam, The Netherlands	Full time, permanent position
Co-investigator in CISNET projects	2005-2020	CISNET is the Cancer Intervention and Surveillance Modelling Network	CISNET is a consortium of NCI-sponsored investigators who use simulation modelling to

			<p>improve our understanding of cancer control interventions.</p> <p>Was involved in these projects:</p> <p>Comparative modelling of lung cancer prevention and control policies</p> <p>Modelling to improve prostate cancer outcomes across diverse populations</p> <p>Comparative modelling: Informing breast cancer control practice policy</p>
Researcher in council funded project	Present	Norway Research Council	Research-based evaluation of the Norwegian Breast Cancer Screening Program (130,000 euros)
Researcher in council funded project	Present	National Medical Research Council	Validation of the Erasmus MC MISCAN-Fadia model for cost-effectiveness analyses of mammography screening in Singapore (70,000 euros)
Consultant (industry)	Present	Bayer	<p>Consultant (30 hours max) for an external UK modeling group on breast modeling</p> <p>(Epidemiological expert consultation of Wickenstones' literature research and economic modeling project in breast cancer screening with various imaging modalities)</p>
Consultant (government)	Present	Netherlands state	Expert witness (Court upper age limit for breast cancer screening)
Member	Present	Erasmus MC Cancer Center and Prevention working group	Research and management at Erasmus MC
Principal Coordinator	Present	Academic Center screening and primary prevention	Bringing benefits of screening and primary prevention to patients and populations at risk

2 MEMBERSHIP OF MANAGING BODY, SCIENTIFIC ADVISORY BODY OR EQUIVALENT STRUCTURE

	Within the past 5 years, have you participated in the internal decision-making of a legal entity or other body with an interest in the field of Activities in question or have you participated in the works of a Scientific Advisory Body with voting rights on the outputs of that entity?	yes	
--	---	-----	--

<i>2a</i>	<i>Participation in a decision-making process</i>			<input checked="" type="checkbox"/>	<input type="checkbox"/>
<i>2b</i>	<i>Participation in the work of a Scientific Advisory Body</i>			<input checked="" type="checkbox"/>	<input type="checkbox"/>
<i>Activity</i>	<i>Time period (from... until month/year)</i>	<i>Name of legal entity or body</i>	<i>Description</i>		
Board member (Scientific Advisory Committee research grant)	Present	Personalised Risk Stratification for Prevention and Early Detection of Breast Cancer	Based in Canada. The project aims to develop a decision-making support tool that will help extend the benefits of screening to those most at risk of cancer		
Board member (Programme committee on prevention research)	Present	Netherlands Organisation for Health Research and Development	National organisation that promotes quality and innovation in the field of health research and health care		
Chair	Present	National Evaluation Team for Breast cancer screening in the Netherlands	The National Evaluation Team collects data on screening outcomes		
Chair (International review research grants committee)	Present	Institut National de Cancer	Based in Paris. The state and science agency specialised in cancer control		

Board member	Present	National Cancer Research Institute (NCRI) Clinical Studies Group CSG Progress Review	Based in the UK, Clinical studies groups are a central part of the UK's cancer research infrastructure. They coordinate the development of trials
Board member	Present	Programmacommissie Borstkankerscreening RIVM	Based in the Netherlands. The National Institute for Public Health and the Environment

3 RESEARCH SUPPORT

	Within the past 5 years, have you, or the research entity (institute or department) to which you belong, received any support from a legal entity or other body with an interest in the field of Activities in question?	yes	
--	---	-----	--

3a	<i>Research support, including grants, rents, sponsorships, fellowships, non-monetary support</i>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
----	---	-------------------------------------	--------------------------

<i>Activity</i>	<i>Time period (from... until month/year)</i>	<i>Name of legal entity or body</i>	<i>Description</i>
EU Horizon 2020 projects (details in question 1)	2015-present	EU-TOPIA (EAST) and 4-IN-THE-LUNG-RUN	A total of 15.2 million euros provided by Horizon 2020
EU projects (details in question 1)	2014-present	CANCON and My PeBS	A total of 12 million, 200 000 euros provided

EU project	2020 onwards	LIVERSCREEN	Screening for liver fibrosis – population-based study across European Countries (6 million euros)
CISNET projects	2005-2020	CISNET is the Cancer Intervention and Surveillance Modelling Network.	CISNET is a consortium of NCI-sponsored investigators. A total of 7.4 million euros provided for three projects
Research council funded project	Present	Norway Research Council	Research-based evaluation of the Norwegian Breast Cancer Screening Program (130,000 euros)
Research council funded project	Present	National Medical Research Council	Validation of the Erasmus MC MISCAN-Fadia model for cost-effectiveness analyses of mammography screening in Singapore (70,000 euros)
Research funded by the Netherlands	Present	ZonMw, KWF Kankerbestrijding	NELSON Randomised Control Trial on lung cancer screening by low-dose spiral CT in high-risk subjects (8 million euros)
Research funded by the Netherlands	Present	ZonMw, KWF Kankerbestrijding	MRI screening trial for women with a high risk of breast cancer and analysis of its cost-effectiveness (375,000 euros)
Dutch nationwide screening programmes	1991-2025	RIVM (Dutch National Institute for Public Health and Environment)	For all 3 nationwide screening programmes together a 'Raamovereenkomst' is signed. Period: 02.04-2020-02.04.2024 – EUR 2.057.836 (excl VAT)

			In 2020 extra for specific research: Breast cancer screening EUR 94.039 (excl VAT) Cervical cancer screening EUR 143.732 (excl VAT)
Canadian research project	Present	Sunnybrook Health Sciences, Canada	Health Technology Assessment for CT lung cancer screening including modelling of outcomes and cost-effectiveness (160,000 euros)
Korean research project	Present	SCOR Global Life	Forecast age specific incidences for DCIS (Carcinoma in situ of the breast) and invasive breast cancer for South Korea under the assumption of various screening scenarios (130,000 euros)
Research funded by the Netherlands	2017 onwards	EARLY-SYNERGY (UMCG Cardiology research institute)	Project funded by the Dutch Heart Foundation (975,000 euros)
Research funded by the Netherlands	Present	KWF (Kankersbestrijding-Dutch Cancer Society)	Towards risk-stratified guidelines for surveillance and treatment of patients with Barrett's oesophagus (160,000 euros)
Research funded by the Netherlands	Present	ZonMw	DENSE Trial- MR Imaging as an Additional Screening Modality for the Detection of Breast Cancer in Women Aged

			50-75 Years with Extremely Dense Breasts (965,000 euros)
Research funded by the Netherlands	Present	ZonMw	PRISMA study: Breast cancer screening. From one-size fits all to a personalised, risk-based approach (675,000 euros)
Research funded by the UK	Present	Cancer Research UK	Evaluating the long-term effectiveness and cost-effectiveness of population-based screening and treatment for prostate cancer: the ProtecT RCTs
EU Advanced Researcher Grant	Present	ROBINSKA (Risk or Benefit in screening for cardiovascular disease)	New and more individualised population-based screening for cardiovascular disease; from a RCT including self-assessments, primary care and coronary artery calcification score to modelling risk-benefit (3.3 million euros)

4 FINANCIAL INTERESTS

	Do you have current investments in a legal entity with an interest in the field of Activities in question, including holding of stocks and shares, and which amounts to more than 10,000 EUR per legal entity or entitling you to a voting right of 5% or more in such legal entity?		no
--	---	--	-----------

4a	Shares	<input type="checkbox"/>	x
4b	Other stock	<input type="checkbox"/>	x

<i>Investment</i>	<i>Name of legal entity</i>	<i>Description</i>

5 INTELLECTUAL PROPERTY

	Do you have any intellectual property rights that might be affected by the outcome of the Activities in question?		no
--	--	--	-----------

<i>5a</i>	<i>Patent, trademarks, or copyrights</i>	<input type="checkbox"/>	x
<i>5b</i>	<i>Others</i>	<input type="checkbox"/>	x

<i>Intellectual property</i>	<i>Description</i>

6 PUBLIC STATEMENTS AND POSITIONS

	<i>Within the past 5 years, have you provided any expert opinion or testimony in the field of Activities in question, for a legal entity or other body as part of a regulatory, legislative or judicial process? Within the past 5 years have you held an office or other position, paid or unpaid, where you represented interests or defended a public statement or position in the field of Activities in question?</i>		no
--	--	--	-----------

6a	For a legal entity or other body as part of a regulatory, legislative or judicial process	<input type="checkbox"/>	x
6b	Represented interests or defended an opinion	<input type="checkbox"/>	x

Activity	Time period (from... until month/year)	Name of legal entity or body	Description

7 INTERESTS OF IMMEDIATE FAMILY MEMBERS

no

7a	To your knowledge, are there any interests of your immediate family members which could be seen as undermining your independence when providing advice to the Commission in the field of the Activities in question?	<input type="checkbox"/>	x
-----------	---	--------------------------	----------

<i>Interests</i>	<i>Time period (from... until month/year)</i>	<i>Name of legal entity or body</i>	<i>Description</i>

7b	<i>If interests of your immediate family members are declared, it is your responsibility to inform them about the collection and publication of information on their interests included in the DoI and to provide them with the privacy statement attached to the guidance for filling in this DoI, and this at the latest when you file the DoI form with the Commission.</i>
-----------	--

8 OTHER RELEVANT INFORMATION

no

8a	Are there any other elements that could be seen as undermining your independence when providing advice to the Commission in the field of the Activities in question?	<input type="checkbox"/>	x
-----------	---	--------------------------	----------

Description:

I hereby declare on my honour that I have read the guidance for completing this form. I also declare on my honour that the information disclosed in this form is true and complete to the best of my knowledge.

Should there be any change to the above information, including as regards upcoming activities, I will promptly notify the competent department or entity and complete a new DoI form describing the changes in question.

I am informed that my personal data are stored, processed and published in accordance with the applicable data protection legislation.

I have been informed that this form may be shared with the European Commission and will be publicly available once the SAPEA report is published.

Date: February 3, 2022_____

Signature: (signature removed for online publication)